Optimized chelator and nanoparticle strategies for high-activity 103Pd-loaded biodegradable brachytherapy seeds

IF 4.4 Q1 CHEMISTRY, INORGANIC & NUCLEAR EJNMMI Radiopharmacy and Chemistry Pub Date : 2024-12-30 DOI:10.1186/s41181-024-00309-4
Emanuel Sporer, Claire Deville, Natan J. W. Straathof, Linda M. Bruun, Ulli Köster, Mikael Jensen, Thomas L. Andresen, Paul J. Kempen, Jonas R. Henriksen, Andreas I. Jensen
{"title":"Optimized chelator and nanoparticle strategies for high-activity 103Pd-loaded biodegradable brachytherapy seeds","authors":"Emanuel Sporer,&nbsp;Claire Deville,&nbsp;Natan J. W. Straathof,&nbsp;Linda M. Bruun,&nbsp;Ulli Köster,&nbsp;Mikael Jensen,&nbsp;Thomas L. Andresen,&nbsp;Paul J. Kempen,&nbsp;Jonas R. Henriksen,&nbsp;Andreas I. Jensen","doi":"10.1186/s41181-024-00309-4","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Brachytherapy (BT) is routinely used in the treatment of various cancers. Current BT relies on the placement of large sources of radioactivity at the tumor site, requiring applicators that may cause local traumas and lesions. Further, they suffer from inflexibility in where they can be placed and some sources reside permanently in the body, causing potential long-term discomfort. These issues can be circumvented through injectable sources, prepared as biodegradable materials containing radionuclides that form solid seeds after administration. The level of radioactivity contained in such seeds must be sufficient to achieve substantial local irradiation. In this report, we investigate two different strategies for biodegradable BT seeds.</p><h3>Results</h3><p>The first strategy entails injectable seeds based on <sup>103</sup>Pd-labeled palladium-gold alloy nanoparticles ([<sup>103</sup>Pd]PdAuNPs). These were prepared by combining [<sup>103</sup>Pd]PdH<sub>2</sub>Cl<sub>4</sub> and AuHCl<sub>4</sub>, followed by lipophilic surface coating and dispersed in lactose octaisobutyrate and ethanol (LOIB:EtOH), in overall radiochemical yield (RCY) of 83%. With the second strategy, [<sup>103</sup>Pd]Pd-SSIB was prepared by conjugating the [16]aneS<sub>4</sub> chelator with lipophilic sucrose septaisobutyrate (SSIB) followed by complexation with [<sup>103</sup>Pd]PdH<sub>2</sub>Cl<sub>4</sub> (RCY = 99%) and mixed with LOIB:EtOH. [<sup>103</sup>Pd]Pd-SSIB was likewise formulated as injectable liquid forming seeds by mixing with LOIB. Both formulations reached activities of 1.0–1.5 GBq/mL and negligible release of radioactivity after injection of 100 µL (100–150 MBq) into aqueous buffer or mouse serum of less than 1% over one month.</p><h3>Conclusion</h3><p>Both strategies for forming injectable BT seeds containing high <sup>103</sup>Pd activity resulted in high radiolabeling yields, high activity per seed, and high activity retention. We consider both strategies suitable for BT, with the preferable strategy using a [16]aneS<sub>4</sub> chelator due to its higher biodegradability.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"9 1","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-024-00309-4","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Radiopharmacy and Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s41181-024-00309-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Brachytherapy (BT) is routinely used in the treatment of various cancers. Current BT relies on the placement of large sources of radioactivity at the tumor site, requiring applicators that may cause local traumas and lesions. Further, they suffer from inflexibility in where they can be placed and some sources reside permanently in the body, causing potential long-term discomfort. These issues can be circumvented through injectable sources, prepared as biodegradable materials containing radionuclides that form solid seeds after administration. The level of radioactivity contained in such seeds must be sufficient to achieve substantial local irradiation. In this report, we investigate two different strategies for biodegradable BT seeds.

Results

The first strategy entails injectable seeds based on 103Pd-labeled palladium-gold alloy nanoparticles ([103Pd]PdAuNPs). These were prepared by combining [103Pd]PdH2Cl4 and AuHCl4, followed by lipophilic surface coating and dispersed in lactose octaisobutyrate and ethanol (LOIB:EtOH), in overall radiochemical yield (RCY) of 83%. With the second strategy, [103Pd]Pd-SSIB was prepared by conjugating the [16]aneS4 chelator with lipophilic sucrose septaisobutyrate (SSIB) followed by complexation with [103Pd]PdH2Cl4 (RCY = 99%) and mixed with LOIB:EtOH. [103Pd]Pd-SSIB was likewise formulated as injectable liquid forming seeds by mixing with LOIB. Both formulations reached activities of 1.0–1.5 GBq/mL and negligible release of radioactivity after injection of 100 µL (100–150 MBq) into aqueous buffer or mouse serum of less than 1% over one month.

Conclusion

Both strategies for forming injectable BT seeds containing high 103Pd activity resulted in high radiolabeling yields, high activity per seed, and high activity retention. We consider both strategies suitable for BT, with the preferable strategy using a [16]aneS4 chelator due to its higher biodegradability.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
优化螯合剂和纳米颗粒策略的高活性103pd负载可生物降解近距离治疗种子
背景:近距离放射疗法(BT)通常用于治疗各种癌症。目前的BT依赖于在肿瘤部位放置大量放射性源,这需要可能造成局部创伤和病变的涂抹器。此外,它们的放置位置不灵活,有些来源会永久留在体内,造成潜在的长期不适。这些问题可以通过注射源来解决,注射源制备成含有放射性核素的可生物降解材料,在给药后形成固体种子。这类种子所含的放射性水平必须足以实现大量的局部辐照。在本报告中,我们研究了两种不同的生物降解BT种子策略。结果第一种策略是基于103Pd标记的钯金合金纳米颗粒([103Pd]PdAuNPs)的可注射种子。通过将[103Pd]PdH2Cl4和AuHCl4结合,然后在亲脂性表面涂覆,分散在辛异丁酸乳酸和乙醇(LOIB:EtOH)中,总放化率(RCY)为83%。采用第二种策略,将[16]aneS4螯合剂与亲脂性蔗糖septaisobutyrate (SSIB)偶联,然后与[103Pd]PdH2Cl4 (RCY = 99%)络合,并与LOIB:EtOH混合制备[103Pd]Pd-SSIB。[103Pd]Pd-SSIB同样与LOIB混合配制成可注射的液体形成种子。将100µL (100 - 150 MBq)注射到低于1%的缓冲液或小鼠血清中,一个月后,两种制剂的活性均达到1.0-1.5 GBq/mL,放射性释放可以忽略不计。结论两种方法均可获得高103Pd活性的BT注射种子,具有较高的放射性标记产量、较高的单粒活性和较高的活性保留率。我们认为这两种策略都适用于BT,由于其较高的生物降解性,使用[16]aneS4螯合剂的优选策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.20
自引率
8.70%
发文量
30
审稿时长
5 weeks
期刊最新文献
Ac-225 radiochemistry through the lens of [225Ac]Ac-DOTA-TATE Development of an automated method for in-house production of sodium 18F-fluoride for injection: process validation as a step toward routine clinical application Synthesis and in vitro evaluation of spirobenzovesamicols as potential 11C-PET tracer alternatives to [18F]FEOBV for vesicular acetylcholine transporter (VAChT) imaging The N-acetyltransferase 10 inhibitor [11C]remodelin: synthesis and preliminary positron emission tomography study in mice Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1